Phaseline

Targets › ADA

ADA (Adenosine deaminase): drug programs, companies and trials

3 programs from 3 companies in 4 trials: 3 Phase 2, 1 Phase 1; Hematology, Infectious disease, Oncology; next expected readout Jun 2027.

Catalyzes the hydrolytic deamination of adenosine and 2-deoxyadenosine. Plays an important role in purine metabolism and in adenosine homeostasis. (UniProt, P00813)

Open in Phaseline: the race on ADA, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
National Heart, Lung, and Blood Institute (NHLBI)Pentostatin
Adenosine deaminase inhibitor
ADAPhase 2Sickle Cell DiseaseDec 2027
National Cancer Institute (NCI)Pentostatin
Adenosine deaminase inhibitor
ADAPhase 2Hairy Cell Leukemia; Primary T-cell Immunodeficiency DisordersJun 2031
City of Hope Medical CenterPentostatin
Adenosine deaminase inhibitor
ADAPhase 1Recurrent Severe Aplastic AnemiaJun 2027

Conditions

Hairy Cell Leukemia (1) Primary T-cell Immunodeficiency Disorders (1) Recurrent Severe Aplastic Anemia (1) Sickle Cell Disease (1)

Modalities

mixed (3)

Companies

National Cancer Institute (NCI) (1) City of Hope Medical Center (1) National Heart, Lung, and Blood Institute (NHLBI) (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.